Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-453943

RESUMO

This study was aimed to investigate the preventing efficacy of the combined using of Er-Shi-Wu-Wei Shan-Hu (ESWWSH) pill, Ru-Yi Zhen-Bao (RYZB) pill, Er-Shi-Wei Chen-Xiang (ESWCX) pill on the focal cere-bral ischemia injury in rats. A total of 80 Sprague-Dawley (SD) rats were randomly divided into four groups. In the sham operation group and the MCAO model group, normal saline was given orally every day (1 mL/100 g). In the positive control group, nimodipine was given orally every day (1.89 mg/100 g). In the drug combination group, ESWWSH pill (7 mg/100 g), RYZB pill (31.5 mg/100 g), ESWCX pill (49 mg/100 g), were separately given in the morning, noon and evening every day. Improved MCAO was used in the model establishment after 7-day intragastri-cal administration. After 24 h brain infarction, TTC method was used in the determination of the cerebral infarct size. Drying and weighing method was used in the calculation of brain water content. Determinations were made on con-tent of NO in ischemic brain issues (nitrate reductase method); activities of SOD in serum (xanthine oxidase method);content of MDA in serum (TBA method); and activities of LDH in serum (pyruvate method). The results showed that compared with the MCAO model group, the combined using of three Tibetan classical prescriptions can obviously re-duce the cerebral infarct size, brain water content and the NO content in brain issues, increase the activity of SOD, reduce the content of MDA, and reduce the activity of LDH in serum. It was concluded that the research preliminari-ly showed that the combined using of ESWWSH pill, RYZB pill and ESWCX pill can protect the ischemic brain tis-sues, such as reducing the cerebral infarct size, alleviating brain edema, and inhibiting oxidative stress reactions.

2.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-459747

RESUMO

This study was aimed to offer a scientific basis for the differentiation and control quality of Castanea mol-lissima Blume shell. The determination was given from the morphological identification, microscopical identification and TLC identification. The results showed that through obtained information such as morphological traits, tissue powder and TLC characteristics, the longitudinal section micrographs of C. mollissima Blume shell and the micro-scopic images of tissue powder had been received. It was concluded that the study provided a reliable reference for the identification of the quality control standards of C. mollissima Blume shell.

3.
Planta Med ; 78(6): 557-64, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22354390

RESUMO

Geniposide, a main iridoid glucoside component of gardenia fruit, has been shown to possess anti-inflammatory activity. However, its potential use for acute lung injury (ALI) has not yet been studied. The aim of this study was to evaluate the anti-inflammatory properties of geniposide using a mouse ALI model. ALI was induced by intranasal injection of lipopolysaccharide (LPS). Pretreatment of mice with geniposide (20, 40, or 80 mg/kg) resulted in a marked reduction in inflammatory cells and total protein concentration in the bronchoalveolar lavage fluid (BALF) of mice. Levels of inflammatory mediators, including tumour necrosis factor- α (TNF- α), interleukin-6 (IL-6), and interleukin-10 (IL-10), were significantly altered after treatment with geniposide. Histological studies using hematoxylin and eosin (H&E) staining demonstrate that geniposide substantially inhibited LPS-induced alveolar wall changes, alveolar haemorrhage, and neutrophil infiltration in lung tissue, with evidence of reduced myeloperoxidase (MPO) activity. In addition, we investigated potential signal transduction mechanisms that could be implicated in geniposide activity. Our results suggest that geniposide may provide protective effects against LPS-induced ALI by mitigating inflammatory responses and that the compound's mechanism of action may involve blocking nuclear factor-kappaB (NF- κB) and mitogen-activated protein kinases (MAPK) signalling pathway activation.


Assuntos
Lesão Pulmonar Aguda/prevenção & controle , Anti-Inflamatórios/uso terapêutico , Gardenia/química , Iridoides/uso terapêutico , Transdução de Sinais/efeitos dos fármacos , Lesão Pulmonar Aguda/induzido quimicamente , Animais , Anti-Inflamatórios/farmacologia , Citocinas/análise , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Frutas/química , Glucosídeos Iridoides/farmacologia , Glucosídeos Iridoides/uso terapêutico , Iridoides/farmacologia , Lipopolissacarídeos/toxicidade , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Pulmão/patologia , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Quinases de Proteína Quinase Ativadas por Mitógeno/efeitos dos fármacos , Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo , NF-kappa B/efeitos dos fármacos , NF-kappa B/metabolismo , Peroxidase/metabolismo , Plantas Medicinais/química , Distribuição Aleatória
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...